Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23074
Title: | Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. | Austin Authors: | Beyer, Leonie;Nitschmann, Alexander;Barthel, Henryk;van Eimeren, Thilo;Unterrainer, Marcus;Sauerbeck, Julia;Marek, Ken;Song, Mengmeng;Palleis, Carla;Respondek, Gesine;Hammes, Jochen;Barbe, Michael T;Onur, Özgür;Jessen, Frank;Saur, Dorothee;Schroeter, Matthias L;Rumpf, Jost-Julian;Rullmann, Michael;Schildan, Andreas;Patt, Marianne;Neumaier, Bernd;Barret, Olivier;Madonia, Jennifer;Russell, David S;Stephens, Andrew W;Roeber, Sigrun;Herms, Jochen;Bötzel, Kai;Levin, Johannes;Classen, Joseph;Höglinger, Günter U;Bartenstein, Peter;Villemagne, Victor L ;Drzezga, Alexander;Seibyl, John;Sabri, Osama;Brendel, Matthias | Affiliation: | Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany Molecular Neuroimaging, inviCRO, New Haven, CT, USA Max- Planck-Institute of Human Cognitive and Brain Sciences, Leipzig, Germany German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Department of Psychiatry, University Hospital Cologne, Cologne, Germany Center for Memory Disorders, University Hospital Cologne, Cologne, Germany Cognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Research Centre Juelich, Juelich, Germany Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia Department of Neurology, Technische Universität München, Munich, Germany Department of Neurology, Hannover Medical School, Hannover, Germany Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany German Center for Neurodegenerative Diseases (DZNE), Munich, Germany Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany InviCRO, LLC, Boston, MA, USA Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Juelich GmbH, Juelich, Germany Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne, Germany Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany Center for Memory Disorders, University Hospital Cologne, Cologne, Germany Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany Life Molecular Imaging GmbH, Berlin, Germany Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany |
Issue Date: | Nov-2020 | Date: | 2020-04-21 | Publication information: | European Journal of Nuclear Medicine and Molecular Imaging 2020; 47(12): 2911-2922 | Abstract: | Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG). Twenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, multi-system atrophy, Parkinson's disease, multi-system atrophy, Parkinson's disease, frontotemporal dementia) and received a dynamic [18F]PI-2620 tau-PET (0-60 min p.i.) and static [18F]FDG-PET (30-50 min p.i.). Regional standardized uptake value ratios of early-phase images (single frame SUVr) and the blood flow estimate (R1) of [18F]PI-2620-PET were correlated with corresponding quantification of [18F]FDG-PET (global mean/cerebellar normalization). Reduced tracer uptake in cortical target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three more and three less experienced readers. Spearman rank correlation coefficients were calculated between early-phase [18F]PI-2620 tau-PET and [18F]FDG-PET images for all cortical regions and frequencies of disagreement between images were compared for both more and less experienced readers. Highest agreement with [18F]FDG-PET quantification was reached for [18F]PI-2620-PET acquisition from 0.5 to 2.5 min p.i. for global mean (lowest R = 0.69) and cerebellar scaling (lowest R = 0.63). Correlation coefficients (summed 0.5-2.5 min SUVr & R1) displayed strong agreement in all cortical target regions for global mean (RSUVr 0.76, RR1 = 0.77) and cerebellar normalization (RSUVr 0.68, RR1 = 0.68). Visual interpretation revealed high regional correlations between early-phase tau-PET and [18F]FDG-PET. There were no relevant differences between more and less experienced readers. Early-phase imaging of [18F]PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a dual time-point protocol for tau-PET imaging could supersede additional [18F]FDG-PET imaging by indexing both the distribution of tau and the extent of neuronal injury. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23074 | DOI: | 10.1007/s00259-020-04788-w | ORCID: | 0000-0002-5832-9875 | Journal: | European journal of nuclear medicine and molecular imaging | PubMed URL: | 32318783 | Type: | Journal Article | Subjects: | Neuronal injury PET Perfusion Tau [18F]PI-2620 |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.